Prevenar 13 receives European approval for an expanded indication to include adults aged 18 to 49 years

    Pfizer announced that Prevenar 13* received European approval for an expanded indication to include adults aged 18 to 49 years for active immunization for the prevention of invasive disease caused by vaccine-type Streptococcus pneumoniae (S. pneumoniae). With previously approved use in infants, young children and adolescents aged 6 weeks to 17 years, as well as adults 50 years of age and older, Prevenar 13 is now the only pneumococcal vaccine in the EU that offers protection against invasive disease from infancy through adulthood. Pfizer noted that the European Commission’s decision to approve this label expansion for Prevenar 13 followed the submission and review of data from an open-label Phase 3 trial of the vaccine in healthy adults aged 18 to 49 years.2 The study – which met all primary and secondary objectives – showed that Prevenar 13 is at least as immunogenic in this age group as it is in adults 60 to 64 years of age, as measured one month after vaccination.

Full media release: July 10, 2013  NEW YORK–(BUSINESS WIRE)– http://www.businesswire.com/news/home/20130710005477/en/Pfizer-Receives-European-Approval-Expand-Prevenar-13*